Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. ALERTS, HOT STOCKS & CHARTS Message Board

RVXCF up 19.41% in October so far..... On the

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 145122
Posted On: 10/05/2016 6:26:23 PM
Avatar
Posted By: growacet
RVXCF up 19.41% in October so far.....

On the TSX (Canada's big board exchange) it ran into the bell and closed at $2.47 CDN which = $1.87 USD at current conversion rates, so it might gap up on the OTC tomorrow.

Anyone interested in doing some DD I have written several blog pieces about it at AvoidTheBag going back to June when it was trading around $1.30 CDN.

I also moderate the RVXCF forum here at IH and would welcome anyone wanted to post questions or commentary.

As I've mentioned before Resverlogix is a biotech engaged in the relatively new field of Epigentics. Everyone knows what Genes are, and Epi is Latin and means above. So in a nutshell Epigenetics is the level above Genetics and it involves writers and erasers, turning things on and off. Think of Genetics as hardware and Epigenetics as software.

The company's lead compound is RVX 208 and it has been named Apabetalone. Apabetalone has been trough pre clinical trials as well as Phase I and Phase II.....they're now in Phase III with a trial called BETonMACE the goal of which is to prove that Apabetalone will reduce the incidence of Major Adverse Cardiac Events in patients with full blown insulin dependent Diabetes, otherwise known as Diabetes Mellitus.

Is it a slam dunk sure thing? No....obviously not, there is no such thing. Fortunately the independent Data Safety Monitoring Board that is overseeing the BETonMACE trial, they just gave the company a positive recommendation on continuing the trial in August citing no safety of efficacy concerns....The trial started dosing patients in Oct/Nov of 2015.

They have major financial backing from Eastern Capital, which is the investment arm of well known Billionaire Kenneth Dart.

One to keep an eye on in any case imo....


(0)
(0)




Check out my blog if you like: Avoid The Bag




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us